Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
From the Editor

Treating the thyroid: Trust the feedback loop

Brian F. Mandell, MD, PhD
Cleveland Clinic Journal of Medicine February 2025, 92 (2) 71-72; DOI: https://doi.org/10.3949/ccjm.92b.02025
Brian F. Mandell
Roles: Editor in Chief
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
  • Article
  • Info & Metrics
  • PDF
Loading

Embedded Image

The mechanisms for cellular effects of thyroid hormones on target tissues in the periphery and on the pituitary gland for negative feedback control of thyroid-stimulating hormone (TSH) release are complex.1 Interaction with genomic receptors directly affects transcriptional elements, other effects are mediated via interactions with the plasma membrane, and some hypermetabolic effects result from direct interaction of thyroid hormones with mitochondria. The systemic clinical effects are myriad. In addition to effects on the basal metabolic rate, thyroid hormones increase expression of beta-adrenergic receptors on the surface of cardiac myocytes2 and decrease the level of circulating low-density lipoprotein (LDL) cholesterol by both stimulating the conversion of hepatocyte cholesterol to bile acids and reducing the level of proprotein convertase subtilisin/kexin type 9,3 an enzyme that degrades hepatic LDL receptors, resulting in increased clearance of circulating LDL cholesterol by the liver. Many factors external to the thyroid gland can modulate these diverse effects, making it difficult to assess the thyroid status of patients solely on clinical grounds.

I contrast the complexity of thyroid hormone functions with the relative simplicity and reliability of the pituitary-thyroid axis that dictates hormone output by the functioning thyroid gland. It is sufficiently straightforward that a thermostat and furnace analogy works reasonably well for almost all patients, and can help guide our clinical reasoning. Measurement of the TSH alone (the thermostat setting) is sufficient for initial screening and follow-up for most patients with suspected or known thyroid disease, yet multiple studies have demonstrated that we order more free thyroxine (T4) and triiodothyronine (T3) levels than are necessary.4 While there are always exceptional situations, we should apparently trust the TSH feedback loop more than we do.

In this issue of the Journal, Bodnar and Saberi5 discuss a patient with apparent hyperthyroidism, which was suspected based on an abnormally low TSH level. In their Symptoms to Diagnosis article, the authors work through with the reader the patient’s clinical course after the initial diagnosis.

But I want to discuss briefly an alternative scenario in which a patient is found to have a slightly elevated TSH. Once the abnormal TSH level is detected (but not before), it is appropriate to check a free T4 level to distinguish the patient with true primary hypothyroidism from the rarer scenario of inappropriate secretion of TSH from the pituitary (or another site). Although routine testing of TSH in asymptomatic patients has been strongly discouraged,6 the symptoms consistent with mild hypothyroidism are diverse and nonspecific enough that testing is often warranted.

Not infrequently, mild elevations in TSH are accompanied by a free T4 level in the normal range. The TSH, when rechecked (as it should be), may be back in the normal range, since low-level TSH elevations may physiologically fluctuate by as much as 40%,7 while free T4 levels may vary by 15%. But the persistent demonstration of what is usually a minimal elevation of TSH with a normal free T4 defines subclinical hypothyroidism.

Many patients with subclinical hypothyroidism can be observed off treatment, with scheduled rechecking of TSH and free T4, because some patients will develop clinical hypothyroidism. The highest estimate of progression of patients to overt hypothyroidism that I found in the literature was 58% over 10 years, but, importantly, this was in patients who all had antiperoxidase thyroid antibodies,8 the major measurable factor predicting ultimate thyroid failure. Other factors that increase the risk of progression include being female, having a higher TSH level (> 10 mIU/L), having heterogeneous thyroid tissue on ultrasonography examination, or having a very low normal T4. But without the presence of antiperoxidase antibodies, the risk of progression is low. In the absence of changing clinical symptoms or otherwise unexplained laboratory findings such as rising LDL cholesterol, repeat measurement of TSH and free T4 every 12 months, or every 6 months in the presence of antiperoxidase antibodies, seems reasonable. There is no need to recheck antibody titers or to check reverse T3 levels.9 Evaluating and following patients with subclinical hyperthyroidism is different, and checking the free T3 level is also important, especially in patients who may have Graves disease.10 Letting trust in the reliability of the physiology dictate our thyroid testing makes good clinical sense, and is cost-effective.

  • Copyright © 2025 The Cleveland Clinic Foundation. All Rights Reserved.

References

  1. ↵
    1. Aranda A
    . Thyroid hormone action by genomic and nongenomic molecular mechanisms. Methods Mol Biol 2025; 2876:17–34. doi:
    OpenUrlPubMed
  2. ↵
    1. Williams LT,
    2. Lefkowitz RJ,
    3. Watanabe AM,
    4. Hathaway DR,
    5. Besch HR Jr.
    . Thyroid hormone regulation of beta-adrenergic receptor number. J Biol Chem 1977; 252(8):2787–2789. pmid:15999
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Bonde Y,
    2. Breuer O,
    3. Lütjohann D,
    4. Sjöberg S,
    5. Angelin B,
    6. Rudling M
    . Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans. J Lipid Res 2014; 55(11):2408–2415. doi:
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Kluesner JK,
    2. Beckman DJ,
    3. Tate JM, et al
    . Analysis of current thyroid function test ordering practices. J Eval Clin Pract 2018; 24(2):347–352. doi:10.1111/jep.12846
    OpenUrlCrossRefPubMed
  5. ↵
    1. Bodnar TW,
    2. Saberi S
    . Thyroid obstacle course: Many challenges from a single gland. Cleve Clin J Med 2025; 92(2):87–93. doi:
    OpenUrlFREE Full Text
  6. ↵
    1. LeFevre ML; US Preventive Services Task Force
    . Screening for thyroid dysfunction: US Preventive Services Task Force recommendation statement. Ann Intern Med 2015; 162(9):641–650. doi:
    OpenUrlCrossRefPubMed
  7. ↵
    1. Karmisholt J,
    2. Andersen S,
    3. Laurberg P
    . Variation in thyroid function tests in patients with stable untreated subclinical hypothyroidism. Thyroid 2008; 18(3):303–308. doi:
    OpenUrlCrossRefPubMed
  8. ↵
    1. Huber G,
    2. Staub JJ,
    3. Meier C, et al
    . Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab 2002; 87(7):3221–3226. doi:10.1210/jcem.87.7.8678
    OpenUrlCrossRefPubMed
  9. ↵
    1. Gomes-Lima C,
    2. Burman KD
    . Reverse T3 or perverse T3? Still puzzling after 40 years. Cleve Clin J Med 2018; 85(6):450–455. doi:
    OpenUrlFREE Full Text
  10. ↵
    1. Lee SY,
    2. Pearce EN
    . Hyperthyroidism: a review. JAMA 2023; 330(15):1472–1483. doi:
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 92 (2)
Cleveland Clinic Journal of Medicine
Vol. 92, Issue 2
1 Feb 2025
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treating the thyroid: Trust the feedback loop
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Treating the thyroid: Trust the feedback loop
Brian F. Mandell
Cleveland Clinic Journal of Medicine Feb 2025, 92 (2) 71-72; DOI: 10.3949/ccjm.92b.02025

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Treating the thyroid: Trust the feedback loop
Brian F. Mandell
Cleveland Clinic Journal of Medicine Feb 2025, 92 (2) 71-72; DOI: 10.3949/ccjm.92b.02025
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The gift of lasting immunity
  • Psychedelics in the medical toolbox?
  • All sulfa drugs are not created equal
Show more From the Editor

Similar Articles

Subjects

  • Endocrinology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire